VANCOUVER, BRITISH COLUMBIA, May 12, 2010 -- Global Health Ventures Inc. (OTCBB: GHLV) (the "Company") is pleased to announce that, it has targeted the development of a new anti-stress medication "Relax-B" using its proprietary sublingual technology.
Global Health Ventures Inc. closed at $0.39 Tuesday, trading 623,499 shares.
Global Health Ventures to Develop Fast Acting Anti-Stress Medication
About Global Health Ventures
Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
NEW YORK & PETACH TIKVAH, Israel, May 12, 2010 -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics is pleased to announce that Dr. Avinoam Kadouri, BrainStorm's Chief Technology Advisor, has been invited to act as a Chairman at the World Stem Cells and Regenerative Medicine Congress being held May 11 -- 13, in London, UK.
BrainStorm Cell Therapeutics Inc. at $0.29 Tuesday, trading 18,430 shares.
BrainStorm To Present At World Stem Cells and Regenerative Medicine Congress
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://stockprofiler.us/index.php?action=main.register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to:http://www.stockprofiler.us, http://www.associatesfortune.com,http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer
-------------------------------------------
Keywords: small cap stock, small cap stock news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile
Posts
No comments:
Post a Comment